This study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Oncologic outcomes as assessed by the rate of negative in-field biopsy at 12 months (primary setting)
Timeframe: 12 months post treatment
Oncologic outcomes as assessed by the rate of advancement to systemic therapy or radical salvage therapies (primary setting)
Timeframe: 3 years post treatment
Oncologic outcomes as assessed by the rate of negative in-field biopsy at 12 months (salvage setting)
Timeframe: 12 months post treatment
Oncologic outcomes as assessed by the rate of progression to systemic therapy or radical salvage therapies (salvage setting)
Timeframe: 3 years post treatment
Change in urinary function as measured by International Prostate Symptom Score (IPSS) questionnaire (primary setting)
Timeframe: Baseline and 12 months post treatment
Change in urinary function as measured by International Prostate Symptom Score (IPSS) questionnaire (salvage setting)
Timeframe: Baseline and 12 months post treatment
Change in erectile function as measured by International Index of Erectile Function (IIEF-5) score questionnaire (primary setting)
Timeframe: Baseline and 12 months post treatment
Change in erectile function as measured by International Index of Erectile Function (IIEF-5) score questionnaire (salvage setting)
Timeframe: Baseline and 12 months post treatment